Role of BCG in Treatment of Bladder Cancer
作者： Abhishek Singhal
DOI:
关键词:
摘要: Aim: This review is written to describe the role of immunotherapy in cancer treatment.Annually, 13,000 deaths result from bladder cancer. Since first report intravesical use BCG 1976, investigators try understand working mechanism as an antitumour modality. Arbitrarily, therapy consists a single course six weekly instillations. Bacillus Calmette-Gue´rin, attenuated strain Mycobacterium bovis, was developed by Calmette and Gue´rin with intention generate vaccine against tuberculosis. Extension treatment (maintenance immunotherapy) used increase efficacy.Results various experiments that after instillation bladder, accumulates near wall internalised processed professional antigen-presenting cells (APCs) (high-grade) tumour cells. Then antigens are presented CD4+ T local synthesis particular set cytokines or cell-mediated immune response. NK may be involve cell killing.
pharmatutor.org参考文章(7)
Aaron T. Ludwig, Jill M. Moore, Yi Luo, Xiaohong Chen, Nicole A. Saltsgaver, Michael A. O’Donnell, Thomas S. Griffith, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: A Novel Mechanism for Bacillus Calmette-Guérin-Induced Antitumor Activity Cancer Research. ,vol. 64, pp. 3386- 3390 ,(2004) , 10.1158/0008-5472.CAN-04-0374
R F M Bevers, K-H Kurth, D H J Schamhart, Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. British Journal of Cancer. ,vol. 91, pp. 607- 612 ,(2004) , 10.1038/SJ.BJC.6602026
NORIKO IKEDA, ICHIRO TOIDA, AKIO IWASAKI, KOJI KAWAI, HIDEYUKI AKAZA, Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): A role of BCG internalization into tumor cells. International Journal of Urology. ,vol. 9, pp. 29- 35 ,(2002) , 10.1046/J.1442-2042.2002.00415.X
A. M. JACKSON, A. B. ALEXANDROFF, R. W. KELLY, A. SKIBINSKA, K. ESUVARANATHAN, S. PRESCOTT, G. D. CHISHOLM, K. JAMES, Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapy Clinical and Experimental Immunology. ,vol. 99, pp. 369- 375 ,(2008) , 10.1111/J.1365-2249.1995.TB05560.X
Henrik Suttmann, Josef Riemensberger, Gabriele Bentien, Dominik Schmaltz, Michael Stöckle, Dieter Jocham, Andreas Böhle, Sven Brandau, Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses Cancer Research. ,vol. 66, pp. 8250- 8257 ,(2006) , 10.1158/0008-5472.CAN-06-1416
Sven Brandau, Josef Riemensberger, Marc Jacobsen, Don Kemp, Weicheng Zhao, Xiuqin Zhao, Dieter Jocham, Timothy L. Ratliff, Andreas B�hle, NK cells are essential for effective BCG immunotherapy International Journal of Cancer. ,vol. 92, pp. 697- 702 ,(2001) , 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z
Y. Luo, H. Yamada, D. P. Evanoff, X. Chen, Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clinical and Experimental Immunology. ,vol. 146, pp. 181- 188 ,(2006) , 10.1111/J.1365-2249.2006.03191.X